The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Tomotherapy for Refractory Brain Metastases
Official Title: Tomotherapy for Refractory Brain Metastases: a Single Arm, Single Center Phase II Trial
Study ID: NCT03027544
Brief Summary: This clinical trial was designed to investigate the efficiency and toxicity of tomotherapy for refractory brain metastases.
Detailed Description: This is a single-arm, single center, phase II trial to investigate the feasibility and toxicity of tomotherapy for refractory brain metastases, which are defined as A: multiple brain metastases(≥3 lesions); B: large brain metastases(with one lesion's volume is no smaller than 6cc or the longest diameter is no shorter than 3cm); C: meningeal metastases.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Chinese Academy of Medical Sciences, Beijing, Beijing, China
Name: Jianping Xiao
Affiliation: Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR